Jazz Pharmaceuticals Plc SEC Filings

Jazz Pharmaceuticals senior vice president of technical operations Mary Elizabeth Henderson reported a sale of company stock in connection with equity compensation. On 11/19/2025, she disposed of 1,331 ordinary shares of Jazz Pharmaceuticals plc at a price of $180.4 per share, as shown in Table I of the filing. The filing states that these shares were sold to cover tax obligations from the vesting of previously granted restricted stock units, which is a common administrative transaction for equity awards. After this sale, she beneficially owned 21,746 ordinary shares, held directly.

Jazz Pharmaceuticals plc director reports share sales and RSU grant. A board member of Jazz Pharmaceuticals filed a Form 4 disclosing several open-market sales of ordinary shares on November 18, 2025 at weighted average prices ranging from $180.0859 to $182.6009. Following these transactions, the reporting person directly beneficially owned 390,826 ordinary shares.

On November 20, 2025, the director received 2,506 restricted stock units at a price of $0.0 under Jazz’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, increasing direct beneficial ownership to 393,332 ordinary shares. Each unit represents a contingent right to one ordinary share and, subject to continuous service and certain additional conditions, will vest in full on July 24, 2026.

Jazz Pharmaceuticals (JAZZ) insider Patricia Carr, SVP and Chief Accounting Officer, reported option-related share transactions. On November 18, 2025, she exercised a non-qualified stock option covering 5,250 ordinary shares at an exercise price of $136.18 per share, increasing her direct shareholdings. On the same date, she reported two sales of ordinary shares: one for 69 shares at $181.66 per share and another for 5,250 shares at $182.07 per share. After these transactions, she directly owned 7,012 ordinary shares of Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (JAZZ) director Rick E. Winningham reported a sale of company stock. On 11/18/2025, he sold 5,500 ordinary shares of Jazz Pharmaceuticals at a price of $180.8597 per share. After this transaction, he beneficially owned 8,893 ordinary shares, held directly. This filing is a routine disclosure of insider trading activity required under securities regulations.

Jazz Pharmaceuticals plc executive Robert Iannone, EVP, Global Head of R&D & CMO, reported a stock sale in a Form 4 filing. On 11/17/2025, he sold 7,159 ordinary shares of JAZZ at $168.26 per share in a transaction carried out under a pre-arranged Rule 10b5-1 trading plan. After this sale, he beneficially owned 72,628 ordinary shares. A footnote notes that he had previously acquired 166 ordinary shares on May 30, 2025 under a Section 423 Employee Stock Purchase Plan.

Jazz Pharmaceuticals plc reported positive top-line results from its Phase 3 HERIZON-GEA-01 trial. The study evaluated Ziihera® (zanidatamab-hrii) with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. These initial results suggest that Ziihera-based combinations may offer a new treatment option in this hard-to-treat cancer setting, pending full data and any future regulatory decisions. Details of the results are provided in a press release attached as an exhibit.

Jazz Pharmaceuticals plc reported higher Q3 results while reshaping its portfolio and balance sheet. Total revenue was $1,126,107, up from $1,054,969 a year ago, driven by product sales. Quarterly net income reached $251,412 versus $215,055 last year as a large income tax benefit offset higher operating costs.

Year to date, the company booked a net loss, reflecting significant acquired in‑process R&D tied to the April acquisition of Chimerix for cash consideration of $944.2 million. Operating cash flow remained strong at $993,255 for the nine months. Cash and cash equivalents were $1,326,070 with investments of $720,000. Total debt stood at $5,361,161, following a voluntary $750.0 million term‑loan repayment in January; the 2026 notes now sit in current maturities.

Pipeline and portfolio updates include FDA approval in October 2025 expanding Zepzelca’s maintenance use in extensive‑stage SCLC, FDA accelerated approval of Modeyso in August 2025, and prior U.S./EU authorizations for Ziihera. In August 2025, Jazz licensed SAN2355 from Saniona with a $42.5 million upfront, expensed to IPR&D.

Jazz Pharmaceuticals plc furnished a Current Report on Form 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.

The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and will not be incorporated by reference into other SEC filings. The report was signed by Executive Vice President and CFO Philip L. Johnson on November 5, 2025.

Jazz Pharmaceuticals appointed Dr. Ted Love to its Board of Directors, effective December 1, 2025, as a Class I director with a term expiring at the 2027 annual general meeting. He will serve on the Audit Committee and the Science and Medicine Committee. Compensation will follow the company’s standard non-employee director program, and he will enter into the company’s standard indemnification agreement.

Kenneth W. O’Keefe will retire from the Board effective December 1, 2025. The company stated his decision was not due to any dispute or disagreement regarding its operations, policies, or practices.